2004

Utility of Casual Postprandial Glucose Levels in Type 2 Diabetes Management

Top

El-Kebbi IM, Ziemer DC, Cook CB, et al. Utility of Casual Postprandial Glucose Levels in Type 2 Diabetes Management. Diabetes Care. 2004;27:335-339. Because readily available glycemic indicators are needed to guide clinical decision-making for intensification of diabetes therapy, our goals were to define the relationship between casual postprandial plasma glucose (cPPG) levels and HbA1c in patients with type 2 diabetes and to determine the predictive characteristics of a convenient glucose cutoff.

Type 2 Diabetes Prevalence in Asian Americans: Results of a National Health Survey

Top

McNeely MJ, Boyko EJ. Type 2 Diabetes Prevalence in Asian Americans: Results of a National Health Survey. Diabetes Care. 2004;27:66-69. Asians are thought to be at high risk for diabetes, yet there is little population-based information about diabetes in Asian Americans. The purpose of this study was to directly compare the prevalence of type 2 diabetes in Asian Americans with other racial and ethnic groups in the U.S. using data from the 2001 Behavioral Risk Factor Surveillance System (BRFSS).

Trends in cardiovascular complications of diabetes

Top

Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA. 2004;292:2495-2499. Despite reductions in cardiovascular disease (CVD) mortality over the past few decades, it is unclear whether adults with and without diabetes have experienced similar declines in CVD risk. OBJECTIVE: To determine whether adults with and without diabetes experienced similar declines in incident CVD in 1950-1995.

Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance

Top

Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes, Obesity and Metabolism. 2004;6:280-285. The second-generation thiazolidinediones (TZDs), rosiglitazone and pioglitazone, significantly decrease fasting plasma glucose and glycosylated haemoglobin (HbA(1c)) levels in patients with diabetes. Recent studies suggest that early treatment with TZDs may prevent the progression from insulin resistance (IR) to type 2 diabetes mellitus (T2DM).

The Tissue Renin-Angiotensin-Aldosterone System in Diabetes Mellitus

Top

Hanes DS, Nahar A, Weir MR. The Tissue Renin-Angiotensin-Aldosterone System in Diabetes Mellitus. Curr Hypertens Rep. 2004;6:98-105. Diabetes is associated with an inordinate burden of cardiovascular and renal disease, which is expected to accelerate during the next few decades. The relationship between the renin-angiotensin system (RAS) and diabetic macrovascular and microvascular disease is well established.

The Significant Effect of Diabetes Duration on Coronary Heart Disease Mortality. The Framingham Heart Study

Top

Fox CS, MD, MPH, Sullivan L, PhD, D'Agostino RB Sr, PhD, Wilson PWF, MD. The Significant Effect of Diabetes Duration on Coronary Heart Disease Mortality. The Framingham Heart Study. Diabetes Care. 2004;27:704-708. The risk of coronary heart disease (CHD) in type 2 diabetes is two- to threefold higher than in the general population, but the effect of diabetes duration on CHD risk has not been well characterized. We hypothesized that duration of diabetes is an important predictor of incident CHD among people with diabetes.

The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications

Top

Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertension.. 2004;17:16S-20S. Clinical trials have demonstrated the benefit of blood pressure (BP) reduction in reducing the risk of cardiovascular and renal complications in patients with diabetes mellitus.

The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes?

Top

Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A.. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabetes Care. 2004;27:1647-1653. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) assesses the effect of pioglitazone, a peroxisome proliferator-activated receptor agonist, with anti-inflammatory and vascular properties, on the secondary prevention of macrovascular events in type 2 diabetes.

The Lipid Triad in Type 2 Diabetes - Prevalence and Relevance of Hypertriglyceridaemia/low High-density Lipoprotein Syndrome in Type 2 Diabetes

Top

Temelkova-Kurktschiev T, Hanefeld M.. The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. Exp Clin Endocrinol Diabetes.. 2004:112:75-79. Cardiovascular disease is the major cause of morbidity and mortality in type 2 diabetes mellitus. Among the established risk factors, the lipid triad (elevated triglycerides, decreased high-density lipoprotein cholesterol, and small dense low-density lipoprotein cholesterol) is a powerful risk factor for atherosclerosis in type 2 diabetes.

The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women

Top

Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164:1422-1426. Epidemiological studies have reported that patients with type 2 diabetes mellitus (DM) have increased mortality and morbidity from cardiovascular diseases, independent of other risk factors. However, most of these studies have been performed in selected patient groups.

1 2 3 4 5 6 7 8 9 Next